患者。IDE397与AMG 193的联用有望成为一种新型、潜在的“first-in-class”合成致死组合。IVX-A12:公布1期临床试验的中期数据Icosavax公司公布了其针对老年人呼吸道合胞病毒(RSV)和人偏肺病毒(hMPV)的候选联合疫苗IVX-A12的1期临床试验的积极中期结果。IVX-A12由Icosavax的RSV预融合F蛋白病毒样颗粒(VLP)候选疫苗IVX-121和Icosavax的hMPV预融合F蛋白VLP候选疫苗IVX-241组成。此次公布的数据显示,IVX-A12在接种后第28天时诱导了老年人对RSV和hMPV的强烈免疫反应,且未发现RSV和hMPV的VLP之间存在免疫干扰的证据。此外,IVX-A12通常耐受性良好,没有发现疫苗相关的严重不良事件。该公司计划在2023年年中启动IVX-A12的2期免疫原性试验。大家都在看▲欲了解更多前沿技术在生物医药产业中的应用,请长按扫描上方二维码,即可访问“药明直播间”,观看相关话题的直播讨论与精彩回放药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务,服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求,欢迎点击下方图片填写具体信息。▲如您有任何业务需求,请长按扫描上方二维码,或点击文末“阅读原文/Read more”,即可访问业务对接平台,填写业务需求信息参考资料(可上下滑动查看)[1] Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. Retrieved May 22, 2023, from https://www.globenewswire.com/news-release/2023/05/19/2672581/0/en/Candel-Therapeutics-Announces-New-Data-from-Ongoing-Phase-1-Clinical-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-26th-Annual.html[2] Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation. Retrieved May 22, 2023, from https://www.globenewswire.com/news-release/2023/05/19/2672795/0/en/Celularity-Announces-Phase-1-Data-Showing-That-MLASC-Therapy-in-Patients-With-Crohn-s-Disease-May-Be-a-Therapeutic-Option-to-Manage-Inflammatory-Bowel-Diseases-and-Prevent-Fistula-.html[3] Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial. Retrieved May 22, 2023, from https://www.globenewswire.com/news-release/2023/05/21/2672909/0/en/Nexcella-Announces-Positive-NXC-201-Clinical-Results-at-ASGCT-100-Overall-Response-Rate-in-DARZALEX-Relapsed-Refractory-AL-Amyloidosis-with-Zero-ICANs-in-Ongoing-NEXICART-1-Phase-1.html[4] Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine. Retrieved May 22, 2023, from https://www.accesswire.com/756225/Neurimmune-Promising-Phase-1-Results-for-Antibody-NI006-in-ATTR-Cardiomyopathy-Published-in-the-New-England-Journal-of-Medicine[5] Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress. Retrieved May 22, 2023, from https://www.businesswire.com/news/home/20230520005001/en[6] Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253. Retrieved May 22, 2023, from https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-doses-first-patient-phase-1-oncology-trial[7] IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors. Retrieved May 22, 2023, from https://www.prnewswire.com/news-releases/ideaya-announces-ind-clearance-enabling-phase-12-clinical-trial-for-combination-of-ide397-and-amg-193-in-mtap-deletion-solid-tumors-301830126.html[8] Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference. Retrieved May 23, 2023, from https://www.businesswire.com/news/home/20230522005158/en[9] Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults. Retrieved May 23, 2023, from https://www.globenewswire.com/news-release/2023/05/22/2673842/0/en/Icosavax-Announces-Positive-Topline-Interim-Phase-1-Results-for-Bivalent-VLP-Vaccine-Candidate-IVX-A12-Against-RSV-and-hMPV-in-Older-Adults.html[10] AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis. Retrieved May 23, 2023, from https://www.globenewswire.com/news-release/2023/05/23/2673951/0/en/AnaMar-Announces-Positive-Phase-I-Data-for-its-Phase-II-Ready-Compound-AM1476-for-Treating-Fibrosis.html[11] PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD. Retrieved May 23, 2023, from https://www.prnewswire.com/news-releases/pharmabcine-receives-ind-approval-from-the-korean-mfds-for-phase-i-clinical-trial-of-its-novel-tie2-agonistic-antibody-in-namd-301831855.html[12] 레고켐, ‘TROP2 ADC’ 고형암 1/2상 “FDA IND 신청” . Retrieved May 23, 2023, from http://www.biospectator.com/view/news_view.php?varAtcId=19076[13] MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies. Retrieved May 23, 2023, from https://www.businesswire.com/news/home/20230523005347/en/[14] NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343. Retrieved May 24, 2023, from https://www.nmdpharma.com/news/nmd1343news[15] Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma. Retrieved May 24, 2023, from https://www.prnewswire.com/news-releases/acepodia-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ace1831-an-anti-cd20-armed-allogeneic-gamma-delta-t-cell-therapy-in-development-to-treat-patients-with-non-hodgkins-lymphoma-301830957.html[16] BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Retrieved May 24, 2023, from https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-updated-encouraging-clinical-and[17] AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema. Retrieved May 24, 2023, from https://aiviva.com/2023/05/aiviva-biopharma-initiates-phase-1-clinical-trial-of-aiv007-for-age-related-macular-degeneration-and-diabetic-macular-edema/[18] Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference. Retrieved May 24, 2023, from https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-presents-preclinical-and-clinical-data-its[19] Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI) . Retrieved May 24, 2023, from https://www.businesswire.com/news/home/20230524005150/en[20] Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors. Retrieved May 25, 2023, from https://www.businesswire.com/news/home/20230524005747/en[21] Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer. Retrieved May 25, 2023, from https://www.eurekalert.org/news-releases/990417免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。分享,点赞,在看,聚焦全球生物医药健康创新